TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05654012

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hormonal assessment
Description: Blood samples will be collected for analyses of sex hormone levels

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hormonal assessment
Description: Blood samples will be collected for analyses of sex hormone levels

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Migraine-related measures
Description: Adolescents with migraine will complete questions regarding their headache frequency and migraine symptoms.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Migraine-related measures
Description: Adolescents with migraine will complete questions regarding their headache frequency and migraine symptoms.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neural assessments
Description: MRI and fMRI scans

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neural assessments
Description: MRI and fMRI scans

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pubertal status
Description: Pubertal status will be assessed using the self-reported Physical Developmental Scale-

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pubertal status
Description: Pubertal status will be assessed using the self-reported Physical Developmental Scale-
Study: NCT06112977

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prepectoral implant-based immediate breast reconstruction
Description: Prepectoral implant based breast reconstruction is an immediate breast reconstruction whereby a fixed volume implant or expander is placed on top of the chest wall muscle (Pectoralis Major) to reconstruct the breast after mastectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prepectoral implant-based immediate breast reconstruction
Description: Prepectoral implant based breast reconstruction is an immediate breast reconstruction whereby a fixed volume implant or expander is placed on top of the chest wall muscle (Pectoralis Major) to reconstruct the breast after mastectomy.
Study: NCT05549544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacing
Description: Biventricular pacing is a widely-established modality to treat heart failure in patients with heart failure
Study: NCT04417049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 MG
Description: All patients will be provided with pentoxifylline 400 mg to be orally ingested twice daily for 8 weeks.
Study: NCT05727397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC28-E
Description: Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
Study: NCT05977634

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Bladder training
Description: Bladder training has 4 components, educating the patient about anatomy, fluid intake control, pelvic floor muscle contractions and increasing the interval between visits to the bathroom

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bladder training
Description: Bladder training has 4 components, educating the patient about anatomy, fluid intake control, pelvic floor muscle contractions and increasing the interval between visits to the bathroom

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Description: A combined electrotherapy device capable of applying transcutaneous electrical nerve stimulation will be used. Each session will take 30 minutes. Patient will visit the hospital twice a week for 6 weeks. An electrical current of 0-50 amperes with a frequency of 20 herz, and a duration of 200 micro seconds will be applied using 50x50 mm surface electordes. The aim is to create a tingling sensation without causing any pain on the tibial nerve, at the ankle level.
Study: NCT04942002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Acetate 40 MG/ML [Depo-Medrol]
Description: Retrobulbar injection performed by care provider

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Standard treatment + placebo
Description: Intravenous Methylprednisolone succinate (1 g daily for 5 days) + paraocular injection of 0.9% saline solution by care provider
Study: NCT04991948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYAD-101
Description: Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: 5-FU, leucovorin and oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
Study: NCT06673277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolonged (2-hour) cryocompression therapy
Description: The cuff of the device will be attached around the knee randomised to receive the treatment as per the manufacturer's instruction. Then the device will be set to apply a standard 30-minute treatment with a temperature of 8 ℃ and intermittent compression of 25-50 mmHg. Following this, and depending on the randomised condition, the treatment will continue for a further 90-minutes with a temperature of either 10 ℃ or 12 ℃ being applied by the device. The level of compression will remain the same (25-50 mmHg) throughout all tests.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolonged (2-hour) cryocompression therapy
Description: The cuff of the device will be attached around the knee randomised to receive the treatment as per the manufacturer's instruction. Then the device will be set to apply a standard 30-minute treatment with a temperature of 8 ℃ and intermittent compression of 25-50 mmHg. Following this, and depending on the randomised condition, the treatment will continue for a further 90-minutes with a temperature of either 10 ℃ or 12 ℃ being applied by the device. The level of compression will remain the same (25-50 mmHg) throughout all tests.
Study: NCT06677372

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body temperature measurement
Description: Comparative analysis of temperature between esophageal temperature and skin temperature
Study: NCT06677112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective surgical staging
Description: Intraoperative Consultation, performed by pathologist and surgeon jointly. The uterus is inspected for extra-corpus spread (cervix, parametria, adnexa, distant). The surgical pathologist will evaluate the uterus according to the IOC Worksheet and promptly notify the surgeon of the results. The IOC will include evaluation for extra-corpus disease, lesion measurement, frozen section (to confirm measured lesion is malignant, cell type, and re-grading of tumor). Non-sentinel nodes will be handled according to institutional standard-of-care practice.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: REFLEX
Description: The surgeon will perform a side-specific lymphadenectomy when there is no mapping on a hemipelvis (no tracer uptake in nodes). If neither side has successful Sentinel Node mapping, the surgeon performs a complete pelvic lymphadenectomy. Surgeons will remove the para-aortic lymph nodes at their discretion.
Study: NCT06676800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqi Gubiao pill
Description: Take 10 pills orally each time, three times a day, after meals, for a continuous period of 12 weeks. Receiving basic treatment: standardized quadruple anti-tuberculosis therapy is administered, with Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide used for the first 2 months, followed by Rifampicin and Isoniazid for the next 4 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yiqi Gubiao Pill placebo
Description: The placebo's appearance and content color are similar to that of Yiqi Gubiao Pill, with the main ingredients being starch and caramel. Take 10 pills orally each time, three times a day, after meals, for a continuous period of 12 weeks. Receiving basic treatment: standardized quadruple anti-tuberculosis therapy is administered, with Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide used for the first 2 months, followed by Rifampicin and Isoniazid for the next 4 months.
Study: NCT06677515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR training
Description: The different VR scenarios comprise the following learning goals: 1) Social cognition. Interpreting social situations, understanding others; 2) Social communication. Express oneself, being understood by others; 3) Social competence. Interacting with others The investigators will use an MSI Raider GE78HX with a GeForce RTX4080 12GB GPU, running Windows 11, Unreal Engine 5.4, and the Meta Quest Link app, with a Meta Quest Pro as a PCVR headset connected via a Meta Quest Link cable. The setup works 100% locally, and no Wi-Fi or internet connection is used on the head-mounted-display or PC. The VR program itself does not store any data and will discard all that has happened inside the program, when restarted.
Study: NCT06676397

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Punction
Description: venous blood sampling

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Punction
Description: venous blood sampling

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Punction
Description: venous blood sampling

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Punction
Description: venous blood sampling

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Punction
Description: venous blood sampling
Study: NCT06675539

Intervention type: DIAGNOSTIC_TEST
Intervention: French version PAWSS
Description: French version of the Prediction of Alcohol Withdrawal Severity Scale
Study: NCT06676228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear of cancer recurrence therapy (FORT)
Description: FORT consists of 6 sessions in total, the scopes of the sessions are detailed below:~Session 1 (Acquiring new skills to cope with Fear of Cancer Recurrence (FCR)) HOMEWORK: Daily practice of progressive muscle relaxation exercise; creation of a thought record~Session 2 (Providing information on symptoms of cancer recurrence and increasing tolerance to uncertainty) HOMEWORK: Listening to recordings of relaxation exercises every day; practising self-calming, keeping a record of thoughts~Session 3 (Developing coping skills) HOMEWORK: Practise guided imagery daily; debunk erroneous beliefs about the benefits of worrying; keep a thought log~Session 4 (Deepening the underlying fears) HOMEWORK: Reading the worst case fear scenario every day, practising daily self-care and mindfulness practices~Session 5 (Moving beyond specific fears) HOMEWORK: Writing goals and priorities for the future~Session 6 (Review and conclusion) Reviewing all the discussed content

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive-behavioural therapy (CBT) group
Description: The cognitive-behavioural therapy (CBT) oriented control group consisted of a total of 6 sessions. The scopes of the sessions are given in detail below.~Session 1: Introduction and cancer-focused psychoeducation with CBT HOMEWORK: Keeping a thought diary~Session 2: Addressing the underlying causes of thoughts HOMEWORK: Keeping a thought diary about underlying beliefs~Session 3: Recognising conflicts HOMEWORK: Task: Keep a diary of thoughts about disagreements (what gives us pleasure and what we should master)~Session 4: Effective communication techniques HOMEWORK: Keeping a diary about the use of the word good enough~Session 5: Discussion of the definitions of anxiety and depression~Session 6: Anger Management HOMEWORK: HOMEWORK: Keeping a diary about the use of the breathing exercise
Study: NCT04352270

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AD printed educational materials
Description: Printed educational materials in Spanish and English about coping with Atopic Dermatitis, specifically geared towards children and parents will be given to participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AD educational videos
Description: Short, educational videos in English and Spanish about coping with Atopic Dermatitis, specifically geared towards children and parents will be developed. There will be Spanish and English versions of the videos, minimal text, comprehensive language, animations, and it will be administered via user friendly platforms or websites.
Study: NCT06245759

Intervention type: OTHER
Intervention: This was a retrospective study and no patient intervention was performed
Description: This was a retrospective study and no patient intervention was performed
Study: NCT06219187

Intervention type: OTHER
Intervention: Questionnaire completion
Description: To meet the study's objective, patients will be asked to complete a questionnaire characterizing their environmental and psychosocial context.~The questionnaire is to be completed by the patients themselves, or by their trusted support person as recorded in their medical records (in the particular case of a deceased patient).~It is estimated that the questionnaire will take around 30 minutes to complete.~Data will also be collected from the medical records of included patients:~* Demographics~* Disease data
Study: NCT06070207

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEP group
Description: Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eTEP group
Description: Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
Study: NCT05982093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Elacestrant 400 mg given orally on a daily and continuous basis for 30 days or until the day before surgery or biopsy (+7 extra days).
Study: NCT05003570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Dosage forms and strengths: 3 mL Vial/1 mg lyophilized powder. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
Study: NCT05982093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elacestrant
Description: Elacestrant 400 mg given orally on a daily and continuous basis for 30 days or until the day before surgery or biopsy (+7 extra days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Monthly triptorelin 3.75 mg powder and solvent for prolonged-release suspension for injection. Each vial contains 3.75 mg of triptorelin (acetate). After reconstitution with 2 ml of solvent, 1 ml of the suspension contains 1.875 mg triptorelin. This drug contains sodium, but less than 1 mmol (23 mg) of sodium per vial.Triptorelin will be administrated on D1 and D29.
Study: NCT06146296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Local Vitamin C injection
Description: An injection of 1-1.5 ml of L-ascorbic acid, locally introduced in relation to the keratinized gingival tissues, with extension to the whole target region successively. The injected area will be massaged for equal distribution of the injected vitamin. Injections will be performed on the first day of retainer delivery (T0), after 1 month (T1), after 3 months (T2), and after 6 months (T3). Hence, a total of 4 local Vit-C injections will be performed over the study period.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vitamin C supplement
Description: Patients will be prescribed a daily oral (systemic) Vit-C supplement to be taken over the follow up period.
Study: NCT06365814

Intervention type: OTHER
Intervention: enhanced recovery after surgery
Description: ERAS is a comprehensive perioperative interventions, including preoperative patient education, prehabilitation, nutritional support, minimally invasive surgery and other methods, can reduce surgical stress and promote patient recovery

Intervention type: OTHER
Intervention: conventional perioperative management
Description: conventional perioperative management
Study: NCT06360874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 40mg
Description: Participants receive 40mg ND-003 tablets once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 placebo 40mg
Description: Participants receive placebo tablet matching to receive 40mg of ND-003.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 80mg
Description: Participants receive 80mg ND-003 tablets once.
Study: NCT06360874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 placebo 80mg
Description: Participants receive placebo tablet matching to receive 80mg of ND-003.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 160mg
Description: Participants receive 160mg ND-003 tablets once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 placebo 160mg
Description: Participants receive placebo tablet matching to receive 160mg of ND-003.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 240mg
Description: Participants receive 240mg ND-003 tablets once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 placebo 240mg
Description: Participants receive placebo tablet matching to receive 240mg of ND-003.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 300mg
Description: Participants receive 300mg ND-003 tablets once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 placebo 300mg
Description: Participants receive placebo tablet matching to receive 300mg of ND-003.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD_ND003_Dose 1
Description: Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD_placebo_Dose 1
Description: Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD_ND003_Dose 2
Description: Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD_placebo_Dose 2
Description: Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD_ND003_Dose 3
Description: Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD_ placebo_Dose 3
Description: Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Food effect_Cohort 1
Description: Firstly orally administrated ND-003 tablets in fast state and then in fed state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Food effect_Cohort 2
Description: Firstly orally administrated ND-003 tablets in fed state and then in fast state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
Study: NCT06371651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Dietary supplement containing creatine and guanidinoacetic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert substance
Study: NCT06048237

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Ultrasound Imaging of the diaphragm
Description: In this reliability study, ultrasound imaging will be utilized by trained physiotherapists to assess diaphragm thickness and excursion. Participants will be positioned in a semi-recumbent position, while the scanning area will be marked with a surgical skin marker according to specific anatomical landmarks recommended, to ensure reproducibility of the procedure. Ultrasound probe will be placed at the zone of apposition to visualize the diaphragm through the liver window.~Diaphragm thickness will be assessed during both full inhalation and exhalation, capturing images in B-mode to measure distance between the diaphragmatic pleura and peritoneal fascia. Diaphragm excursion will be assessed during tidal volume diaphragmatic breathing, using M-mode to track the craniocaudal displacement of the diaphragm during respiratory cycle. Data obtained will contribute to the evaluation of the reliability of diaphragm thickness and excursion measurements for potential future clinical applications.
Study: NCT05604469

Intervention type: DIAGNOSTIC_TEST
Intervention: Isolation of skin microbiota
Description: Isolation of skin microbiota including, Staphylococcus epidermidis, Propionibacterium acnes, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pyogenes and Candida.

Intervention type: DIAGNOSTIC_TEST
Intervention: Isolation of skin microbiota
Description: Isolation of skin microbiota including, Staphylococcus epidermidis, Propionibacterium acnes, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pyogenes and Candida.

Intervention type: DIAGNOSTIC_TEST
Intervention: Isolation of skin microbiota
Description: Isolation of skin microbiota including, Staphylococcus epidermidis, Propionibacterium acnes, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pyogenes and Candida.

Intervention type: DIAGNOSTIC_TEST
Intervention: Isolation of skin microbiota
Description: Isolation of skin microbiota including, Staphylococcus epidermidis, Propionibacterium acnes, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pyogenes and Candida.
Study: NCT05242653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pressure by a cotton swab
Description: All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with pressure by a cotton swab.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stromal hydration with the balanced salt solution（BSS）
Description: All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with stromal hydration.
Study: NCT06242743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scalpel blade needles
Description: Patients were assigned to IANB injection by double scalpel blade bevel needles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard blade needles
Description: Patients were assigned to IANB injection by standard blade bevel needles.